The Sanofi Ventures-backed vaccine development company has listed on Nasdaq, with its shares rising on the first day of trading.

Icosavax, a US-based vaccine developer backed by pharmaceutical firm Sanofi, floated in a $182m initial public offering on Thursday on the Nasdaq Global Select Market.

The company issued some 12 million shares having priced them in the middle of the IPO’s $14 to $16 range. They opened at $29 each before closing at $35, representing a 133% increase.

Spun out of University of Washington’s Institute for Protein Design, Icosavax is developing vaccines for respiratory illnesses using virus-like particles. Its…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn